STAG2 and myelodysplastic syndrome: Interestingly, trisomy 8 was significantly associated with STAG2 mutations (P = 0.03) and conferred a shorter duration of response to venetoclax-based therapy regardless of prior treatment in patients with “CMP pattern” MDS but not those with “GMP pattern” MDS (n = 53 patients treated with venetoclax-based therapies for whom immunophenotypic data were available) (Supplementary Fig. 6a, Supplementary Data 3).